ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Apo-A1

Apo-A1

概要

Name:Apolipoprotein A-I
Target Synonym:Epididymis Secretory Sperm Binding Protein,Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
AP1-H5225 Human Human Apo-A1 Protein, His Tag
AP1-H5225-structure
AP1-H5225-sds
ACRO Quality

Synonym Name

Apolipoprotein A-I,APOA1,MGC117399

Background

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Fx-5A Fx-5A Phase 1 Clinical Kinemed Inc Cardiovascular Diseases Details
Pelacarsen IONIS-681257; ISIS-681257; TQJ-230 Phase 3 Clinical Ionis Pharmaceuticals Inc, Akcea Therapeutics Inc Kidney Diseases; Hyperlipoproteinemias; Cardiovascular Diseases; Hepatic Insufficiency; Aortic Valve Stenosis Details
Zerlasiran SLN-360 Phase 2 Clinical Silence Therapeutics Plc Atherosclerosis; Dyslipidemias; Cardiovascular Diseases; Hyperlipidemias Details

This web search service is supported by Google Inc.

totopphone